Dompe Announces the European Medicines Agency Has Granted Orphan Drug Designation to Its rhNGF-Based Treatment for Retinitis Pigmentosa

Published: Jul 01, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

MILAN--(BUSINESS WIRE)--Dompé, a leading company in research & development of novel treatment solutions for rare diseases, announces its investigational drug based on the recombinant human nerve growth factor (rhNGF) for the treatment of retinitis pigmentosa (RP) has been granted orphan drug designation.

Help employers find you! Check out all the jobs and post your resume.

Back to news